Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) P/B ratio
Guardant Health, Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 57.3× (January 2023) — the current reading is the lowest in ten years.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 18.7× | (59.19%) |
| FY2022 | 45.8× | 191.79% |
| FY2021 | 15.7× | 62.34% |
| FY2020 | 9.7× | 9.14% |
| FY2019 | 8.9× | 274.86% |
| FY2018 | 2.4× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 32 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| GH Guardant Health, Inc. | n/m |
| ICLR ICON PLC compare | 1.7× |
| RVTY Revvity Inc. compare | 2.3× |
| LH Labcorp Holdings Inc. compare | 3.3× |
| DGX Quest Diagnostics Incorporated compare | 3.5× |
| CRL Charles River Laboratories International, Inc. compare | 4.6× |
| ILMN Illumina, Inc. compare | 10.1× |
| MEDP Medpace Holdings, Inc. compare | 30.3× |
| MTD Mettler-Toledo International, Inc. compare | 2,631× |
| Diagnostics & Research industry median | 3.4× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on GH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement